S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
Critical asset just had biggest fall on record (Ad)
A collection of the insights Warren Buffett offered in his annual letter Saturday
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
Laser breakthrough could send stock soaring 2,467% (Ad)
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Macron booed by French farmers who blame him for not doing enough to support agriculture
Laser breakthrough could send stock soaring 2,467% (Ad)
MILAN FASHION PHOTOS: Ferragamo, Dolce&Gabbana conceal and reveal, balance transparency with cover
Tax-free status of movie, music and games traded online is on table as WTO nations meet in Abu Dhabi
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
Critical asset just had biggest fall on record (Ad)
A collection of the insights Warren Buffett offered in his annual letter Saturday
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
Laser breakthrough could send stock soaring 2,467% (Ad)
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Macron booed by French farmers who blame him for not doing enough to support agriculture
Laser breakthrough could send stock soaring 2,467% (Ad)
MILAN FASHION PHOTOS: Ferragamo, Dolce&Gabbana conceal and reveal, balance transparency with cover
Tax-free status of movie, music and games traded online is on table as WTO nations meet in Abu Dhabi
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
Critical asset just had biggest fall on record (Ad)
A collection of the insights Warren Buffett offered in his annual letter Saturday
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
Laser breakthrough could send stock soaring 2,467% (Ad)
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Macron booed by French farmers who blame him for not doing enough to support agriculture
Laser breakthrough could send stock soaring 2,467% (Ad)
MILAN FASHION PHOTOS: Ferragamo, Dolce&Gabbana conceal and reveal, balance transparency with cover
Tax-free status of movie, music and games traded online is on table as WTO nations meet in Abu Dhabi
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
Critical asset just had biggest fall on record (Ad)
A collection of the insights Warren Buffett offered in his annual letter Saturday
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
Laser breakthrough could send stock soaring 2,467% (Ad)
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Macron booed by French farmers who blame him for not doing enough to support agriculture
Laser breakthrough could send stock soaring 2,467% (Ad)
MILAN FASHION PHOTOS: Ferragamo, Dolce&Gabbana conceal and reveal, balance transparency with cover
Tax-free status of movie, music and games traded online is on table as WTO nations meet in Abu Dhabi
NASDAQ:DBTX

Decibel Therapeutics (DBTX) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$4.90
$5.11
50-Day Range
$4.91
$5.23
52-Week Range
$1.61
$5.40
Volume
1.26 million shs
Average Volume
122,002 shs
Market Capitalization
$123.39 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.06

DBTX stock logo

About Decibel Therapeutics Stock (NASDAQ:DBTX)

Decibel Therapeutics, Inc., a clinical-stage biotechnology company, engages in discovering and developing transformative treatments for hearing and balance disorders. The company's product candidates and programs focuses on three areas, such as Gene Therapies for Congenital, Monogenic Hearing Loss designed to restore functional cells within the cochlea to address hearing disorders caused by single gene mutations; Gene Therapies for Hair Cell Regeneration designed to replace lost hair cells within the inner ear to address acquired hearing loss and balance disorders; and Otoprotection Therapeutic in clinical development to prevent hearing loss in cancer patients undergoing chemotherapy with cisplatin. Its lead gene therapy product candidate is DB-OTO to provide hearing to individuals born with profound hearing loss due to mutation of the otoferlin gene. The company is also developing DB-ATO and AAV.201, a gene therapy program designed to restore balance in patients with bilateral vestibulopathy by regenerating lost hair cells within the vestibule; DB-020 for the prevention of cisplatin-induced hearing loss, which is in Phase 1b clinical trial; AAV.103 to restore hearing in individuals with a gap junction beta-2 (GJB2) deficiency; AAV.104 to restore hearing in individuals with stereocilin (STRC) deficiency; and cochlear hair cell regeneration program, an AAV-based gene therapy that utilizes cell-selective expression of reprogramming factors to convert supporting cells into outer hair cells. Decibel Therapeutics, Inc. has a strategic collaboration with Regeneron Pharmaceuticals, Inc. to develop gene therapies for monogenic forms of congenital hearing loss. The company was formerly known as Hearing Inc. and changed its name to Decibel Therapeutics, Inc. in April 2014. Decibel Therapeutics, Inc. was incorporated in 2013 and is headquartered in Boston, Massachusetts. As of September 25, 2023, Decibel Therapeutics, Inc. operates as a subsidiary of Regeneron Pharmaceuticals, Inc.


DBTX Stock News Headlines

The Best Noise-Cancelling Headphones
Shocking Bank Secret of the Ultra-Rich
A 229-year-old banking secret is behind some of the wealthiest, most powerful dynasties in American history –  here's how it could help you in 2024.
Decibel Therapeutics' CVR Appears Around Fair Value
Shocking Bank Secret of the Ultra-Rich
A 229-year-old banking secret is behind some of the wealthiest, most powerful dynasties in American history –  here's how it could help you in 2024.
DBTX - Decibel Therapeutics, Inc.
See More Headlines
Receive DBTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Decibel Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/10/2021
Today
2/25/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:DBTX
Fax
N/A
Employees
68
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$8.06
High Stock Price Target
$23.00
Low Stock Price Target
$2.00
Potential Upside/Downside
+64.2%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
4 Analysts

Profitability

Net Income
$-63,010,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$3.28 per share

Miscellaneous

Free Float
16,182,000
Market Cap
$123.39 million
Optionable
Not Optionable
Beta
-0.43
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

  • Dr. Laurence E. Reid Ph.D. (Age 59)
    Pres & CEO
    Comp: $742.98k
  • Ms. Anna Trask M.A.Ms. Anna Trask M.A. (Age 65)
    Exec. VP & Chief People Officer
    Comp: $481.23k
  • Mr. John J. Lee (Age 55)
    Exec. VP & Chief Devel. Officer
    Comp: $596.15k
  • Mr. M. Charles Liberman
    Co-Founder & Member of Scientific Advisory Board
  • Dr. Gabriel Corfas
    Co-Founder & Member of Scientific Advisory Board
  • Dr. Ulrich Müller
    Co-Founder & Member of Scientific Advisory Board
  • Dr. Albert S. B. Edge (Age 68)
    Co-Founder & Member of Scientific Advisory Board
  • Mr. James B. Murphy (Age 66)
    Interim CFO, Principal Financial Officer & Principal Accounting Officer
  • Ms. Elaine Cope M.B.A.
    VP of Operations
  • Mr. Geoff Horwitz
    VP of Corp. Devel. & Head of Bus. Devel.














DBTX Stock Analysis - Frequently Asked Questions

Should I buy or sell Decibel Therapeutics stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Decibel Therapeutics in the last year. There are currently 4 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" DBTX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in DBTX, but not buy additional shares or sell existing shares.
View DBTX analyst ratings
or view top-rated stocks.

What is Decibel Therapeutics' stock price target for 2024?

4 analysts have issued 12 month price targets for Decibel Therapeutics' stock. Their DBTX share price targets range from $2.00 to $23.00. On average, they anticipate the company's stock price to reach $8.06 in the next twelve months. This suggests a possible upside of 64.2% from the stock's current price.
View analysts price targets for DBTX
or view top-rated stocks among Wall Street analysts.

How were Decibel Therapeutics' earnings last quarter?

Decibel Therapeutics, Inc. (NASDAQ:DBTX) released its quarterly earnings data on Wednesday, November, 10th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.43) by $0.23.

When did Decibel Therapeutics IPO?

(DBTX) raised $100 million in an initial public offering (IPO) on Friday, February 12th 2021. The company issued 5,900,000 shares at a price of $16.00-$18.00 per share. Citigroup, BMO Capital Markets, SVB Leerink and Barclays acted as the underwriters for the IPO.

This page (NASDAQ:DBTX) was last updated on 2/25/2024 by MarketBeat.com Staff